** Shares of drug developer vTv Therapeutics VTVT.O rise 19.2% to $17.70, their biggest one-day percentage win in more than one year
** Co says U.S. FDA has lifted clinical hold on development of cadisegliatin, an oral adjunctive therapy to insulin therapy for treatment of type 1 diabetes
** Co plans to resume its late-stage trial for the therapy after submitting protocol amendment to shorten trial from 12 to 6 months
** Up to last close, stock down 12.9% in last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。